
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Dnmt3L CRISPR/Cas9 KO Plasmid (m) | sc-424871 | 20 µg | $397.00 |
Dnmt3l encodes Dnmt3L, a catalytically inactive cofactor that stimulates the de novo DNA methyltransferases DNMT3A and DNMT3B to establish and maintain DNA methylation patterns during development. In mouse, Dnmt3L is highly relevant to germline epigenetic programming, where it supports methylation of retrotransposons and imprint control regions, contributing to genome stability and parent-of-origin–specific gene regulation. Through these functions, Dnmt3L integrates into epigenetic regulation pathways that coordinate chromatin state, transcriptional silencing, and meiosis-associated reprogramming. Dysregulation of DNMT3L-associated methylation processes is linked to defects in imprinting, altered transposon repression, and broader epigenome instability that can influence developmental phenotypes and disease-relevant epigenetic states.
Dnmt3L CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Dnmt3l gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Dnmt3l together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Dnmt3l open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Dnmt3L protein expression.
This CRISPR knockout system enables efficient generation of Dnmt3l-deficient cell models for investigation of Dnmt3L signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.